世界におけるがん免疫療法及びパイプラインインサイト...市場調査レポートについてご紹介

1. Introduction to Cancer Immunotherapy (Page 6)

2. Mechanism of Cancer Immunotherapy (Page 11)
2.1 Genetic engineering
2.2 Hybridoma Technology
2.3 Humanization of Monoclonal Antibodies
2.4 Overcoming the HAMA Response via Modern Technology

3. Types of Cancer Immunotherapy (Page 14)
3.1 Monoclonal Antibodies
3.2 Checkpoint Inhibitors
3.3 Vaccination
3.4 Non Specific Immunotherapies

4. Why Need for Cancer Immunotherapy (Page 23)

5. Global Cancer Immunotherapy Market Overview (Page 26)

6. Cancer Immunotherapy Market Dynamics (Page 33)
6.1 Favorable Market Drivers
6.2 Key issues to be Discussed
6.3 Future of Cancer Immunotherapy

7. Cancer Monoclonal Antibodies Clinical Pipeline by Phase & Country (Page 41)
7.1 Clinical Pipeline Overview
7.2 Clinical Pipeline Insight: Research till Registration
7.3 Marketed Cancer Monoclonal Antibodies

8. Cancer Vaccine Clinical Pipeline by Phase & Country (Page 1088)
8.1 Clinical Pipeline Overview
8.2 Clinical Pipeline Insight: Research till Registration
8.3 Marketed Cancer Vaccines

9. Oncolytic Viruses Clinical Pipeline by Phase & Country (Page 1640)
9.1 Clinical Pipeline Overview
9.2 Clinical Pipeline insight: Research till Registration

10. Cancer Cytokine Therapy Clinical Trial Insight by Phase & Country (Page 1714)
10.1 Clinical Pipeline Overview
10.2 Clinical Pipeline Insight: Research till Preregistration
10.3 Marketed Cancer Cytokines Threapy

11. Cancer Cell Therapy Clinical Trial Insight by Phase & Country (Page 1844)
11.1 Clinical Pipeline Overview
11.2 Clinical Pipeline Insight: Research till Preregistration
11.3 Marketed Cancer Cell Therapy

12. Competitive Landscape: Business Overview & Product Pipeline (Page 1977)
12.1 Advaxis
12.2 Celldex Therapeutics
12.3 Dendreon Corporation
12.4 Galena Biopharma
12.5 ImmunoCellular Therapeutics
12.6 ImmunoGen
12.7 Inovio Pharmaceuticals
12.8 Merck
12.9 NeoStem Oncology
12.10 NewLink Genetics
12.11 Northwest Biotherapeutics
12.12 Novartis
12.13 Peregrine Pharmaceuticals
12.14 Roche
12.15 Seattle Genetics

List of Figures

Figure 1-1: Introduction to Cancer Therapies
Figure 1-2: Key Events in the History of Cancer Immunotherapy
Figure 2-1: Mechanism of Cancer Immunotherapy
Figure 3-1: Type of Cancer Immunotherapy

Figure 5-1: Cancer Immunotherapy Market Category
Figure 5-2: Cancer Immunotherapy Market (US$ Billion), 2014-2020
Figure 5-3: Cancer Immunotherapy Market by Region (%), 2014 & 2020
Figure 5-4: Regulatory Milestones for Cancer Immunotherapy

Figure 7-1: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (%), 2014
Figure 7-2: Cancer Monoclonal Antibodies Clinical Pipeline by Phase (Number), 2014

Figure 8-1: Cancer Vaccine Clinical Pipeline by Phase (%), 2014
Figure 8-2: Cancer Vaccine Clinical Pipeline by Phase (Number), 2014

Figure 9-1: Oncolytic Viruses Clinical Pipeline by Phase (%), 2014
Figure 9-2: Oncolytic Viruses Clinical Pipeline by Phase (Number), 2014

Figure 10-1: Cancer Cytokines Therapy Clinical Pipeline by Phase (%), 2014
Figure 10-2: Cancer Cytokines Therapy Clinical Pipeline by Phase (Number), 2014

Figure 11-1: Cancer Cell Therapy Clinical Pipeline by Phase (%), 2014
Figure 11-2: Cancer Cell Therapy Clinical Pipeline by Phase (Number), 2014

Figure 12-1: Advaxis Clinical Pipeline
Figure 12-2: Celldex Therapeutics Clinical Pipeline
Figure 12-3: Galena Biopharma Clinical Pipeline
Figure 12-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 12-5: ImmunoGen Clinical Pipeline
Figure 12-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 12-7: NewLink Genetics Corporation Clinical Pipeline
Figure 12-8: Northwest Biotherapeutics Clinical Pipeline
Figure 12-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 12-10: Seattle Genetics Clinical Pipeline